Drug
Cabotegravir (CAB)
Cabotegravir (CAB) is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Completed1
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Trials by Status
completed133%
unknown133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruiting
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778
completed
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
NCT04518228
unknown
GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV
NCT03462810
Clinical Trials (3)
Showing 3 of 3 trials
NCT07473778
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT04518228
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
NCT03462810
GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3